EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever

EQT completed its final sell-down in Galderma, generating aggregate gross proceeds of approximately CHF 4.9 billion. Under EQT's ownership Galderma accelerated revenue growth, increased R&D investment, completed one of Europe’s largest IPOs in 2024 and its share price has nearly tripled since the IPO, signaling strong investor demand and meaningful value crystallization for private-market investors.

Analysis

The EQT sell-down crystallizes private-market-to-public arbitrage that will echo across deal markets: realized liquidity removes a seller overhang and creates dry powder that EQT can redeploy into new buyouts or follow-ons within 6–18 months, which should raise bidding pressure for premium dermatology assets and compress entry multiples for smaller PE shops. On a days-to-weeks timescale expect muted EQT stock volatility as the market prices in distributable gains; on a 3–12 month horizon the key driver is how EQT converts the proceeds into fee-earning assets or returns capital to shareholders.

For competitors and supply chain participants there are two non-obvious winners. First, specialist CDMOs and API suppliers stand to benefit as incumbent dermatology players scale R&D and product rollouts—this is a multi-year demand tail for high-spec formulation capacity and regulatory-compliant manufacturing. Second, publicly traded dermatology/med-tech firms face steeper M&A comps: the recent public value uplift sets a higher anchor for strategic buyers and could accelerate consolidation among mid-cap peers within 12–24 months.

Tail risks that would reverse the move include a near-term slowdown in Galderma’s organic growth (12–24 months) or any regulatory/reimbursement shocks in key markets; both would force mean reversion of richly priced comps. Also watch for EQT governance actions—accelerated buybacks or special dividends would be supportive, whereas aggressive reinvestment into lower-return sectors would cap upside.

Net positioning should reflect a two–pronged view: capture immediate relief/re-rating at the private-to-public junction while hedging execution and regulatory risk over the next 6–18 months. Entry windows: consider initiating on any 5–10% post-sale profit-taking and scale into confirmed redeployment announcements or buyback/dividend declarations.

Key Decisions for Investors

• Buy EQT (EQT) — 6–12 month horizon. Position size 3–5% NAV. Rationale: removal of secondary overhang + redeployment optionality should re-rate fee-earning capacity. Target +20–30% upside; stop-loss 12% below entry. Add if EQT announces buyback/dividend or new healthcare platform investment within 90 days.
• Long specialist CDMO exposure — Lonza (LONN.SW) or sector ETF — 9–18 month horizon. Trade via 12–24 month call spread to limit premium. Rationale: uplift in dermatology product launches increases demand for formulation and manufacture. Expect asymmetric 15–35% upside vs limited premium cost; cut if order momentum stalls for two consecutive quarters.
• Pair trade: long Galderma (SIX: GALN) calls / short Estée Lauder (EL) calls — 3–6 month horizon. Rationale: capture continued re-rating of science-backed dermatology vs cyclical beauty. Structure as debit call spread on GALN financed by short EL calls to aim for ~2:1 reward:risk; unwind on signs of broad consumer discretionary resilience or if GALN misses quarterly revenue growth.